TRDA - NASDAQ

Entrada Therapeutics, Inc.

TRDA·NASDAQ

$6.58

-0.90%

HealthcareBiotechnology

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$255.44M

EPS-3.4700

P/E Ratio-1.90

Earnings Date08/05/2026

trda

Accumulated Other Comprehensive Income (Loss)

Last Annual Value

652.00K

3-Year CAGR

32%

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Entrada Therapeutics, Inc. Competitors Analysis of Accumulated Other Comprehensive Income (Loss)

TRDA · NASDAQ

Company	Accumulated Other Comprehensive Income (Loss)	CAGR 3Y	CAGR 5Y	CAGR 10Y
Entrada Therapeutics, Inc. NASDAQ:TRDA	652.00K	49.5%	N/A	N/A
Humacyte, Inc. NASDAQ:HUMA	0.00	N/A	N/A	N/A
Immuneering Corporation NASDAQ:IMRX	81.33K	N/A	N/A	N/A
Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT	0.00	N/A	N/A	N/A
Allogene Therapeutics, Inc. NASDAQ:ALLO	269.00K	N/A	N/A	N/A
Caribou Biosciences, Inc. NASDAQ:CRBU	103.00K	50.9%	N/A	N/A
Enanta Pharmaceuticals, Inc. NASDAQ:ENTA	-339.00K	N/A	N/A	N/A
Foghorn Therapeutics Inc. NASDAQ:FHTX	24.00K	N/A	N/A	N/A
OmniAb, Inc. NASDAQ:OABI	12.00K	-37.9%	N/A	N/A
Pyxis Oncology, Inc. NASDAQ:PYXS	53.00K	-5.6%	N/A	N/A
Cassava Sciences, Inc. NASDAQ:SAVA	0.00	N/A	N/A	N/A

Entrada Therapeutics, Inc. Fair Value Envelope

TRDA · NASDAQ

Our analysis suggests that TRDA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.58, this represents a potential HIDDEN relative to our calculated worth for Entrada Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $6.58

Related Guides

Blog Categories

Continue your TRDA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.